SS-31 and MOTS-c: Two Different Paths in Mitochondrial Research

SS-31 and MOTS-c appear together in discussions of mitochondria, but they represent different scientific ideas. SS-31, also known as elamipretide, has been studied for its interaction with cardiolipin in the inner mitochondrial membrane. MOTS-c is a mitochondrial-derived peptide investigated as a signal connecting metabolic conditions with cellular responses. Sharing a research theme does not make them interchangeable.

The most useful comparison therefore starts with three questions: what does each molecule interact with, which experimental systems have been studied, and how far do those findings extend? Those questions provide a clearer picture than describing either compound simply as an energy peptide.

SS-31: studying the membrane environment

Mitochondrial energy production depends on an organized membrane environment. Cardiolipin is a lipid involved in that environment, including interactions with proteins participating in electron transfer. In mechanistic experiments, researchers investigated how SS-31 affected the cardiolipin–cytochrome c interaction using model membranes and isolated mitochondrial preparations.

The results supported a specific mechanism: SS-31 limited the peroxidase activity associated with that interaction while preserving cytochrome c’s electron-transfer function. Measurements included respiration and ATP synthesis, rather than a person’s subjective sense of energy. This distinction matters because a molecular explanation can guide research without establishing the same effect in every disease or population. Birk and colleagues, 2014.

MOTS-c: studying metabolic communication

MOTS-c is a 16-amino-acid peptide first described in a short open reading frame associated with mitochondrial 12S ribosomal RNA. Its original characterization connected mitochondrial genetic information with metabolic regulation. Cell experiments implicated pathways linked to AMPK, an important regulator of cellular energy responses; mouse experiments examined insulin sensitivity and the consequences of a high-fat diet.

These findings established a research direction, not a clinical equivalence to exercise or a treatment recommendation. A change in glucose handling in a mouse model is a defined experimental result. It should not be converted into a promise of improved metabolism in otherwise healthy people. Lee and colleagues, 2015.

Subsequent work showed that MOTS-c could relocate to the nucleus during metabolic stress and influence gene-expression responses. This adds another layer to the comparison: SS-31 research often examines the membrane machinery of mitochondria, while MOTS-c research also examines communication between cellular compartments. Neither description captures every reported action, but the distinction is useful. Kim and colleagues, 2018.

What the exercise findings mean

A 2021 study measured naturally occurring MOTS-c during exercise in a small group of young men. The same paper also included experiments involving administered MOTS-c in mice. Those are related but different forms of evidence: observing an endogenous response in humans does not show that administering a peptide reproduces exercise’s benefits in humans.

This is a common source of confusion in research summaries. The phrase “human study” can refer to a measured biomarker, an association, or a randomized intervention. Before drawing a practical conclusion, identify which of those the paper actually reports. For MOTS-c, the exercise findings support further investigation of metabolic signaling; they do not establish a substitute for physical activity. Reynolds and colleagues, 2021.

SS-31 has a specific clinical history

Elamipretide has progressed beyond laboratory experiments into clinical development. A small randomized crossover study in Barth syndrome did not meet its two primary endpoints during the controlled phase. Improvements were subsequently reported during its open-label extension. Reporting both parts is essential: an extension without a concurrent placebo group answers a different question from the randomized comparison. TAZPOWER primary report.

On September 19, 2025, the US FDA granted accelerated approval to Forzinity, an elamipretide medicine, for a specific Barth syndrome indication in patients weighing at least 30 kg. This is a defined regulatory decision about a particular medicinal product and population. It is not approval of retail research-grade SS-31 for general fatigue, athletic performance or longevity. FDA approval announcement.

A comparison that preserves the evidence

For researchers, the appropriate starting point is the experimental question. A membrane-function experiment and a metabolic-signaling experiment may need different controls, endpoints and interpretation, even when both concern mitochondria. A shared product category should not decide the study design.

Evidence limitations

This article does not establish a head-to-head efficacy ranking or a benefit from combining the two compounds. The cited work spans isolated preparations, cell models, animals, observational human measurements and disease-specific clinical trials. Results cannot be transferred automatically between these settings. Product identity and analytical documentation are important for reproducible research, but they do not themselves demonstrate clinical safety or effectiveness.

Reviewed September 12, 2026. This article is educational and does not provide instructions for human use.

Primary references

• Birk et al. — cardiolipin, cytochrome c and mitochondrial function, 2014.
• Lee et al. — original MOTS-c metabolic study, 2015.
• Kim et al. — MOTS-c nuclear translocation, 2018.
• Reynolds et al. — MOTS-c and exercise-related experiments, 2021.
• TAZPOWER — randomized trial and open-label extension.
• FDA — accelerated approval of Forzinity, 2025.